08:12 AM EDT, 10/31/2024 (MT Newswires) -- The European Commission on Thursday said it has fined Teva Pharmaceutical Industries ( TEVA ) 462.6 million euros ($502.8 million) for allegedly delaying competition to its medicine for the treatment of multiple sclerosis, Copaxone.

"The Commission found that Teva artificially extended the patent protection of Copaxone and systematically spread misleading information about a competing product to hinder its market entry and uptake," the commission said.

Teva did not immediately reply to a request for comment from MT Newswires.

Price: 18.49, Change: -0.10, Percent Change: -0.54